NICE has cleared the way for bevacizumab to be used by the NHS to treat colorectal cancer for the first time, thanks to the availability of lower-cost biosimilar versions of the drug. In recently ...
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
NICE has today published final draft guidance recommending bevacizumab with chemotherapy for people with metastatic colorectal cancer. This is the first time NICE has been able to recommend ...
RAHWAY, N.J., December 17, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback